Ose Immunotherapeutics
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Jan 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 11 to 30, 2027 · next Jan 11
- 1 fee due Feb 1, 2027The maintenance fee for Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer (US 11,713,356) comes due Feb 1, 2027. Unpaid by Aug 2, 2027, it lapses early.
- 2 fees due Apr 1 to 8, 2027 · next Apr 1
- 1 fee due Jul 30, 2027The maintenance fee for Use of anti-human SIRPa v1 antibodies and method for producing anti-SIRPa v1 antibodies (US 11,884,723) comes due Jul 30, 2027. Unpaid by Jan 31, 2028, it lapses early.
- 1 fee due Sep 12, 2027The maintenance fee for Antibodies and Polypeptides Directed Against CD127 (US 11,926,671) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
- 1 fee due Nov 14, 2027The maintenance fee for Method for Manufacturing a Stable Emulsion for Peptide Delivery (US 11,981,713) comes due Nov 14, 2027. Unpaid by May 15, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,689,444 | Recombinant Monovalent Antibodies In force · High confidence | In force | High confidence | |
| US 8,785,138 | Monovalent Ligands of the Human CD28 Receptor In force · High confidence | In force | High confidence | |
| US 8,785,604 | ANTI-CD28 Humanized Antibodies In force · High confidence | In force | High confidence | |
| US 9,587,023 | Recombinant Monovalent Antibodies In force · High confidence | In force | High confidence | |
| US 10,364,287 | Anti-CD28 Humanized Antibodies In force · High confidence | In force | High confidence | |
| US 9,447,182 | Antibodies Directed Against the Alpha Chain of IL7 Receptor - Their Use for the Preparation of Drug Candidates In force · High confidence | In force | High confidence | |
| US 10,434,157 | Therapeutic multi-peptides T specific immune therapy for treatment of brain metastasis In force · From the USPTO record | In force | From the USPTO record | |
| US 10,428,152 | Antibodies directed against CD127 In force · From the USPTO record | In force | From the USPTO record | |
| US 11,440,964 | Method for treating a pathological condition involving the activation or proliferation of CD127 positive cells with an anti-CD127 antibody In force · From the USPTO record | In force | From the USPTO record | |
| US 12,371,502 | Antibodies directed against CD127 In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 28: 4 patents in force now held by others · 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
14 pending · 7 abandoned · 12 no status recorded